Cobicistat
drugOn this page
Also known as Cobicistat component of evotazCobicistat component of genvoyaCobicistat component of prezcobixCobicistat component of rezolstaCobicistat component of stribildCobicistat component of symtuzaCobicistat on silicon dioxideCobicistat, (r,r,s)-GS-9350Tybost
Summary
Cobicistat (CHEMBL2095208) is an approved small-molecule P450 inhibitor (ATC V03AX03); indicated across 16 conditions including hiv infectious disease and aids.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V03AX03
- Indications: 16 conditions
- Clinical trials: 52
- Chemistry: 776 Da · C40H53N7O5S2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2095208 |
| Name | Cobicistat |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 25151504 |
| ChEBI | CHEBI:72291 |
| ATC | V03AX03 |
| Molecular formula | C40H53N7O5S2 |
| Molecular weight | 776 |
| InChIKey | ZCIGNRJZKPOIKD-CQXVEOKZSA-N |
SMILES: CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)CC5=CC=CC=C5
IUPAC name: 1,3-thiazol-5-ylmethyl N-[(2R,5R)-5-[[(2S)-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]-4-morpholin-4-ylbutanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
ChEBI definition: A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2S)-2-({(2-isopropyl-1,3-thiazol-4-yl)methylcarbamoyl}amino)-4-(morpholin-4-yl)butanoic acid with the amino group of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-amino-1,6-diphenylhexan-2-yl]carbamate. Acts as a pharmacoenhancer in treatment of HIV-1 by inhibiting P450 enzymes that metabolise other medications..
Pharmacological roles (ChEBI): P450 inhibitor.
Also known as: Cobicistat, Cobicistat component of evotaz, Cobicistat component of genvoya, Cobicistat component of prezcobix, Cobicistat component of rezolsta, Cobicistat component of stribild, Cobicistat component of symtuza, Cobicistat on silicon dioxide, Cobicistat, (r,r,s)-, GS-9350, Tybost, COBICISTAT
Patent coverage: 1,119 distinct patent families (2,767 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Cytochrome P450 2D6, Cytochrome P450 3A4, Replicase polyprotein 1ab, Broad substrate specificity ATP-binding cassette transporter ABCG2.
Bioactivity
ChEMBL activities: 4 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| CYP3A4 | 6.82 | IC50 | 150 | nM | CHEMBL_ACT_13914612 |
| P0DTD1 | 5.66 | Kd | 2200 | nM | CHEMBL_ACT_25952224 |
| P0DTD1 | 5.17 | IC50 | 6700 | nM | CHEMBL_ACT_25952152 |
| CYP2D6 | 5.04 | IC50 | 9200 | nM | CHEMBL_ACT_13914683 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
16 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| HIV infectious disease | 4 | MONDO:0005109 | EFO:0000764 |
| AIDS | 3 | MONDO:0012268 | EFO:0000765 |
| pneumocystosis | 3 | MONDO:0019121 | EFO:0007448 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| malaria | 1 | MONDO:0005136 | EFO:0001068 |
| acute lymphoblastic leukemia | 1 | MONDO:0004967 | EFO:0000220 |
| exocrine pancreatic carcinoma | 1 | MONDO:0005192 | EFO:0002618 |
| pancreatic neoplasm | 1 | MONDO:0021040 | EFO:0003860 |
| pancreatic ductal adenocarcinoma | 1 | MONDO:0005184 | MONDO:0005184 |
| acute biphenotypic leukemia | 1 | MONDO:0020322 | MONDO:0019460 |
| non-small cell lung carcinoma | 0 | MONDO:0005233 | EFO:0003060 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 52.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 26 |
| PHASE4 | 11 |
| Not specified | 5 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
| PHASE3 | 2 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05078671 | PHASE4 | RECRUITING | Pharmacokinetic Boosting of Olaparib to Improve Exposure, Tolerance and Cost-effectiveness |
| NCT05748093 | PHASE4 | RECRUITING | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat |
| NCT06337032 | PHASE4 | RECRUITING | A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments |
| NCT02180438 | PHASE4 | COMPLETED | An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal |
| NCT02198443 | PHASE4 | COMPLETED | Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open. |
| NCT02404233 | PHASE4 | UNKNOWN | Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects |
| NCT02470650 | PHASE4 | WITHDRAWN | Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive |
| NCT02503462 | PHASE4 | TERMINATED | Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals |
| NCT03123848 | PHASE4 | COMPLETED | A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants |
| NCT04064632 | PHASE4 | UNKNOWN | RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled Infection |
| NCT04388904 | PHASE4 | COMPLETED | Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) |
| NCT02016924 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV |
| NCT02431247 | PHASE3 | COMPLETED | A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects |
| NCT02499978 | PHASE2/PHASE3 | WITHDRAWN | Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity |
| NCT04252274 | PHASE3 | UNKNOWN | Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 |
| NCT04065399 | PHASE1/PHASE2 | RECRUITING | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation |
| NCT06014489 | PHASE2 | RECRUITING | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML |
| NCT02859558 | PHASE2 | COMPLETED | Early ART to Limit Infection and Establishment of Reservoir |
| NCT03045861 | PHASE2 | COMPLETED | Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults |
| NCT03480646 | PHASE1/PHASE2 | COMPLETED | ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer |
| NCT01619527 | PHASE1 | COMPLETED | A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions |
| NCT01837719 | PHASE1 | COMPLETED | Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat |
| NCT01896622 | PHASE1 | COMPLETED | The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers |
| NCT02203461 | PHASE1 | COMPLETED | Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication |
| NCT02219217 | PHASE1 | COMPLETED | SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers |
| NCT02277600 | PHASE1 | COMPLETED | A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI) |
| NCT02307656 | PHASE1 | COMPLETED | Taste Properties of Atazanavir and Cobicistat |
| NCT02475135 | PHASE1 | COMPLETED | Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination |
| NCT02565888 | PHASE1 | COMPLETED | A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat |
| NCT02578550 | PHASE1 | COMPLETED | A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants |
| NCT02661373 | PHASE1 | COMPLETED | First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor |
| NCT02818348 | PHASE1 | COMPLETED | Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients |
| NCT02984852 | PHASE1 | COMPLETED | Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants |
| NCT03864406 | PHASE1 | COMPLETED | Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers |
| NCT04236453 | PHASE1 | TERMINATED | A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents |
| NCT04263350 | PHASE1 | COMPLETED | A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time |
| NCT04322214 | PHASE1 | COMPLETED | Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat |
| NCT04661397 | PHASE1 | COMPLETED | A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate Agents |
| NCT04718805 | PHASE1 | COMPLETED | A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions |
| NCT05236738 | PHASE1 | COMPLETED | A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).